These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8698535)

  • 1. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction.
    Canale D; Giorgi PM; Lencioni R; Morelli G; Gasperi M; Macchia E
    Int J Androl; 1996 Feb; 19(1):28-32. PubMed ID: 8698535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
    Kunelius P; Lukkarinen O
    Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China.
    He L; Wen J; Jiang X; Chen H; Tang Y
    Andrologia; 2011 Jun; 43(3):208-12. PubMed ID: 21486416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential penile ultrasound monitoring of patients treated with chronic intracavernous prostaglandin E1.
    Hirsch IH; Schanne FJ; Carsello J; Bagley DH; Alexander AA
    Urology; 1995 Jun; 45(6):1037-41. PubMed ID: 7771005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years.
    Hauck EW; Altinkilic BM; Schroeder-Printzen I; Rudnick J; Weidner W
    Andrologia; 1999; 31 Suppl 1():99-103. PubMed ID: 10643527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
    Loran OB; Segal AS; Shcheplev PA
    Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
    Chen RN; Lakin MM; Montague DK; Ausmundson S
    J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?
    Bassiem MA; Ismail IY; Salem TA; El-Sakka AI
    Urology; 2021 Feb; 148():173-178. PubMed ID: 33017615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1].
    Lemaire A; Buvat J
    Prog Urol; 1998 Jun; 8(3):388-91. PubMed ID: 9689672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study.
    Porst H; Buvat J; Meuleman E; Michal V; Wagner G
    Int J Impot Res; 1998 Dec; 10(4):225-31. PubMed ID: 9884918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence.
    Ishii N; Watanabe H; Irisawa C; Kikuchi Y; Kubota Y; Kawamura S; Suzuki K; Chiba R; Tokiwa M; Shirai M
    J Urol; 1989 Feb; 141(2):323-5. PubMed ID: 2913354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: possible alternative to penile implants in selected patients.
    Truss MC; Becker AJ; Thon WF; Kuczyk M; Djamilian MH; Stief CG; Jonas U
    Eur Urol; 1994; 26(1):40-5. PubMed ID: 7925528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of color-coded duplex ultrasound diagnosis (angiodynography) after intraurethral administration of PgE1 in erectile dysfunction].
    Wechsel HW; Strohmaier WL; Bichler KH
    Urologe A; 1995 Jan; 34(1):46-8. PubMed ID: 7879322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction.
    Martínez-Piñeiro L; Cortés R; Cuervo E; López-Tello J; Cisneros J; Martínez-Piñeiro JA
    Eur Urol; 1998 Oct; 34(4):350-4. PubMed ID: 9748684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavernous injection of alprostadil for erectile dysfunction.
    Med Lett Drugs Ther; 1995 Sep; 37(958):83-4. PubMed ID: 7674992
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.